OncoMed's Demcizumab Phase 1b Clinical Trials Show

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OncoMed's Demcizumab Phase 1b Clinical Trials Show Encouraging Safety and Anti-Tumor Activity at ESMO

MADRID and REDWOOD CITY, Calif, Sept. 28, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED ), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, presented safety and efficacy data from two Phase 1b clinical trials of demcizumab (anti-DLL4, OMP-21M18) in pancreatic cancer and non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain.

Results from the Phase 1b studies demonstrate that demcizumab, in combination with standard-of-care chemotherapy, is well tolerated, especially in patients where the company's risk mitigation, monitoring and truncated dosing strategies have been employed. Encouraging tumor response rates were presented at ESMO from a study of demcizumab with gemcitabine or gemcitabine plus Abraxane ® (paclitaxel protein-bound particles for injectible suspension) (albumin bound) in patients with first-line pancreatic cancer, and from the study of demcizumab plus pemetrexed and carboplatin for the first-line treatment of Stage III/IV NSCLC. OncoMed's Phase 1b studies identified the demcizumab dosing schedules for the company's planned randomized Phase 2 proof-of-concept trials.

"As we advance to Phase 2 clinical trials of demcizumab, we have successfully identified strategies that result in both favorable tolerability and compelling response rates," said Jakob Dupont, M.D., OncoMed's Chief Medical Officer. "To date, sixty-four patients have been enrolled and treated on the demcizumab truncated dosing schedule that will be used in our randomized Phase 2 studies. The majority of these patients have now been followed for greater than 100 days without any moderate-to-severe cardiopulmonary toxicities and a number of patients remain on treatment."  

"Based on the data generated from our Phase 1b studies in pancreatic and non-small cell lung cancer we have identified a dosing regimen with impressive anti-tumor activity and an acceptable safety profile. We have confidence that these data enable the advancement of both programs into planned randomized Phase 2 studies in pancreatic cancer and NSCLC.  Results from our Phase 1b demcizumab program not only signal the potential safety and anti-tumor activity for this drug, but also provide encouragement for the potential of an anti-cancer stem cell hypothesis," said Paul J. Hastings, Chairman and Chief Executive Officer. 

Demcizumab Phase 1b in Pancreatic Cancer

In 47 pancreatic cancer patients evaluable for safety, the combination of demcizumab and gemcitabine, with or without nab-paclitaxel, was generally well tolerated. Fatigue, nausea and vomiting were the most common drug related toxicities.  Among 22 evaluable patients who received the demcizumab + gemcitabine + nab-paclitaxel combination, nine (41%) achieved partial responses and 10 had stable disease as measured by RECIST criteria, resulting in an overall clinical benefit rate of 86 percent. Median progression-free survival for the demcizumab + nab paclitaxel + gemcitabine combination has not yet been reached at the Phase 2 dose. Six  patients were still undergoing treatment at the final dose tested of 3.5mg/kg as of July 15, 2014.

OncoMed implemented a truncated dosing schedule for demcizumab following an observation of reversible cardiopulmonary toxicities in earlier studies. Additionally, all patients are being followed with cardiac monitoring using B-type natriuretic peptide (BNP) (an early indicator of cardiotoxicity) and echocardiography. Cardioprotective medications, such as angiotensin-converting enzyme inhibitors, were administered to patients with rising BNPs. The truncated dosing and cardiac monitoring strategies appear to have mitigated the risks of cardiopulmonary toxicity. None of the 26 pancreatic cancer patients treated in this manner have developed moderate-to-severe heart failure or pulmonary hypertension.  

OncoMed's Phase 1b clinical study of demcizumab in pancreatic cancer patients has completed enrollment. By the end of this year, the company currently plans to initiate a large international randomized Phase 2 clinical trial utilizing the truncated 3.5mg/kg dose of demcizumab every two weeks.  The truncated dosing and cardiac monitoring strategies will be further evaluated in the randomized Phase 2 study for pancreatic cancer.

Data from OncoMed's Phase 1b clinical study of demcizumab in pancreatic cancer patients were presented by Dr. Manuel Hidalgo, M.D., Ph.D., Director of the Centro Integral Oncológico Clara Campal (CIOCC), START Madrid and lead investigator for the Phase 1b demcizumab clinical study, in the "Gastrointestinal tumours, non-colorectal" discussion session in a poster titled: "A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM) & Gemcitabine (GEM) +/- Paclitaxel Protein Bound Particles (nab-paclitaxel) in Patients with Pancreatic Cancer" (#616PD).

Demcizumab Phase 1b in NSCLC

Demcizumab in combination with pemetrexed and carboplatin was generally well tolerated in 39 chemotherapy-naïve NSCLC patients evaluable for safety in the Phase 1b clinical study. Nausea, fatigue and hypertension were the most common demcizumab-related toxicities. The addition of carboplatin and pemetrexed did not appear to impact demcizumab pharmacokinetics. Of 33 patients evaluable for efficacy, one (3%) had a complete response, 15 (45%) had a partial response and 13 (39%) had stable disease per RECST criteria.  The overall clinical benefit rate was 88 percent. Median progression-free survival was not reached as of July 25, 2014 for the patients treated with the Phase 2 regimen. Eight patients treated with demcizumab once every three weeks at doses of 5mg/kg or 7.5mg/kg plus pemetrexed and carboplatin on-study and in some cases continued administration of protocol defined chemotherapy off-study have remained progression free for greater than 300 days.

The Phase 1b implemented truncated dosing of demcizumab along with cardiac monitoring using BNP and echocardiography following the occurrence of reversible cardiopulmonary toxicity in earlier studies.  The combination of truncated dosing and cardiac monitoring appears to prevent the onset of late cardiopulmonary toxicity.  Of note, the truncated dosing schedule did not appear to impact drug efficacy: among the 14 evaluable patients, who received demcizumab on a truncated dosing schedule, one had a complete response, seven had a partial response, five achieved stable disease and one had progressive disease resulting in an overall clinical benefit rate in this subset of patients of 93 percent.

Truncated demcizumab dosing at 5mg/kg once every three weeks is ongoing with three patients at this dose level still on therapy as of the data cut off of July 25, 2014. The company expects to initiate a large international randomized Phase 2 clinical trial of demcizumab with carboplatin and pemetrexed in first-line non-squamous NSCLC by the end of the year.  The planned demcizumab dose for the Phase 2 study will be 5mg/kg once every three weeks.

Data from the Phase 1b study of demcizumab in NSCLC were presented on September 27 in a poster titled: "A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM), Pemetrexed (PEM) & Carboplatin (CARBO) in Patients with First-line Non-Squamous NSCLC" (#1240P).

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-Notch1 (OMP-52M51), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28), which target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two other antibodies in preclinical development, anti-DLL4/anti-VEGF bispecific (OMP-305B83) and anti-RSPO3 (OMP-131R10), with Investigational New Drug filings planned for late 2014 or early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com .

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding OncoMed Pharmaceuticals, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including OncoMed's expectations regarding the advancement of demcizumab into randomized Phase 2 clinical trials in NSCLC and pancreatic cancer; the timing of Phase 2 clinical trials for demcizumab; the tolerability of demcizumab at efficacious doses; the ability of OncoMed's dosing and cardiac monitoring strategies to mitigate demcizumab-related toxicities while maintaining efficacy; the potential of demcizumab to significantly impact treatment and the clinical outcome of patients with cancer, especially pancreatic cancer or NSCLC; the potential of anti-cancer stem cell therapeutics; and the timing of Investigational New Drug filings for OncoMed's anti-DLL4/anti-VEGF bispecific and anti-RSPO3 antibodies. Such forward-looking statements involve substantial risks and uncertainties that could cause OncoMed's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval process; OncoMed's dependence on its collaboration partners, including Celgene, GSK and Bayer, for the funding of its partnered programs; OncoMed's ability to raise additional capital to support the development of its unpartnered programs; OncoMed's dependence on the development and marketing efforts of its partners for the commercial success of its partnered product candidates; OncoMed's reliance on third parties to conduct certain preclinical studies and all of its clinical trials; OncoMed's reliance on single source third-party contract manufacturing organizations to manufacture and supply its product candidates; OncoMed's ability to validate, develop and obtain regulatory approval for companion diagnostics; OncoMed's ability to achieve market acceptance and commercial success of its product candidates once regulatory approval is achieved; OncoMed's ability to discover, develop and commercialize additional product candidates; the ability of competitors to discover, develop or commercialize competing products more quickly or more successfully; OncoMed's dependence on its Chairman and Chief Executive Officer, its Chief Scientific Officer, its Chief Medical Officer and other key executives; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate OncoMed's patents or proprietary rights; and the ability of OncoMed's proprietary rights to protect its technologies and product candidates. OncoMed undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to OncoMed's business in general, see OncoMed's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed with the Securities and Exchange Commission (SEC) on March 18, 2014, OncoMed's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2014, filed with the SEC on May 8, 2014, and OncoMed's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2014, filed with the SEC on August 7, 2014.

Investor Contact: OncoMed Pharmaceuticals Shari Annes Investor Relations (650) 888-0902 Media Inquiries: BCC Partners Michelle Corral or Karen L. Bergman (415) 794-8662 or (650) 575-1509 or

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 255

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 69

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 136

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 131

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 148

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Fold Health's AI: Revolutionizing Patient Care Dynamics

Updated Category News Views 140

AI's Role in Healthcare: From Insight to Action Healthcare's got a resource issue, plain and simple. It's like trying to fill a bathtub with a hole in it—clinicians are swamped, burnout is high, and patients aren't getting the attention they need. Enter Fold Health's AI operating layer, launched with the ambition to realign the equation. Not Just Another Tech Buzzword...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 63

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 165

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 120

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading

Top 5 Most Recently Viewed Articles

Radiant Striping's Community Commitment through Service Initiatives

Updated Category News Views 144

Radiant Striping's Charitable Impact on the Community Radiant Striping, a veteran-owned company, is making waves in their community through generous donations of parking lot striping and other services to local organizations. It's not just about the perfect paint job; it’s about building safer, more welcoming spaces for families and visitors alike. A Mission Rooted in...

Continue Reading
Supernus Pharmaceuticals Announces Participation in Key Healthcare Event

Updated Category News Views 86

Supernus Pharmaceuticals' Participation in the Healthcare Conference Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a dedicated biopharmaceutical company, is excited to announce its upcoming participation in a significant healthcare conference. The conference will take place soon, and prominent figures from the company, including Jack Khattar, President and CEO, are set...

Continue Reading
CTC Celebrated as Top Veteran-Friendly Employer in 2024

Updated Category News Views 70

Concurrent Technologies Corporation Recognized in 2024 Concurrent Technologies Corporation (CTC) is thrilled to announce its inclusion in the U.S. Veterans Magazine’s Top Veteran-Friendly Employers list for 2024. This achievement marks the fourth consecutive year that CTC has received this important recognition. How U.S. Veterans Magazine Evaluates Employers Each year,...

Continue Reading
Chimerix Announces Inducement Grant of Stock Options

Updated Category News Views 188

Chimerix Announces Inducement Grant of Stock Options Chimerix (NASDAQ:CMRX), a prominent biopharmaceutical company, has announced a notable inducement award for a newly hired employee. This grant includes non-statutory stock options totaling 150,000 shares of the company's common stock, underscoring Chimerix's dedication to attracting top talent in the competitive biotech...

Continue Reading
EarFun Showcases Cutting-Edge Wireless Audio Innovations

Updated Category News Views 620

Discover the Latest Innovations from EarFun at CES 2025 EarFun, a prominent name in wireless audio technology, is set to unveil a range of cutting-edge products that will redefine the audio experience. Their participation in CES 2025 promises to highlight significant advancements that cater to diverse listening needs. Innovative AI-Powered Features The spotlight will be...

Continue Reading